Drug intelligence / Profile preview

ST-AH-01

Development stage: Unknown
Lead developer: Stero Biotechs
Modality: Small Molecules

Overview

ST-AH-01 is a proprietary cannabidiol (CBD)-based small molecule formulation developed by Stero Biotechs for the treatment of autoimmune hepatitis (AIH). The drug is designed as a maintenance therapy to facilitate steroid reduction and mitigate the severe side effects associated with long-term corticosteroid use. By leveraging the immunomodulatory and anti-inflammatory properties of CBD, ST-AH-01 aims to maintain disease remission in AIH patients while reducing their dependency on steroids. The formulation is currently being evaluated in Phase 2 clinical trials in Israel.

Other names: cannabidiol formulation

Targets

CNR1 (Cannabinoid receptor 1)GPR55 (G protein-coupled receptor 55)

Beyond the preview

Go deeper on ST-AH-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ST-AH-01.

Explore the full profile